不同脓毒症相关急性肾损伤定义对其发生率和结局影响的系统评价与Meta分析
该系统评价与Meta分析检索1990年至2023年Medline、Medline Epub、EMBASE和Cochrane CENTRAL,纳入189项随机临床试验和前瞻性队列研究,其中154项报告脓毒症相关急性肾损伤发生率、共150,978例参与者。合并发生率为0.40(95%CI 0.37-0.42),仅采用风险-损伤-衰竭-丧失-终末期肾病、急性肾损伤网络与改善全球肾脏病预后定义时为0.52(95%CI 0.48-0.56);以接受肾脏替代治疗定义时最低(0.26,95%CI 0.24-0.28),以急性肾损伤网络评分定义时最高(0.57,95%CI 0.45-0.69;P<0.01)。67项研究、29,455例参与者报告至少一项脓毒症相关急性肾损伤结局,末次随访时死亡比例为0.48(95%CI 0.43-0.53),存活者中仍接受透析比例为0.10(95%CI 0.04-0.17)。脓毒症相关急性肾损伤在ICU脓毒症患者中常见,死亡和持续肾功能损害风险高,其发生率和结局随所用急性肾损伤定义显著不同。
要点
- ICU脓毒症患者脓毒症相关急性肾损伤合并发生率为0.40(95%CI 0.37-0.42);仅采用风险-损伤-衰竭-丧失-终末期肾病、急性肾损伤网络与改善全球肾脏病预后定义时为0.52(95%CI 0.48-0.56)。
- 发生率因急性肾损伤定义及是否纳入尿量标准而显著不同:以接受肾脏替代治疗定义时最低(0.26,95%CI 0.24-0.28),以急性肾损伤网络评分定义时最高(0.57,95%CI 0.45-0.69;P<0.01)。
- 67项研究、29,455例参与者报告结局:末次随访时脓毒症相关急性肾损伤患者死亡比例为0.48(95%CI 0.43-0.53)。
- 存活者中仍接受透析的比例为0.10(95%CI 0.04-0.17),提示持续肾功能损害。
适用人群与场景
- 纳入随机临床试验和前瞻性队列研究,对象为入住ICU的成人脓毒症和/或脓毒症相关急性肾损伤患者;检索1990年至2023年Medline、Medline Epub、EMBASE和Cochrane CENTRAL。
研究设计与关键结果
- 系统评价与Meta分析,共纳入189项研究;154项报告脓毒症相关急性肾损伤发生率,包括150,978例参与者,合并发生率为0.40(95%CI 0.37-0.42)。
- 仅采用风险-损伤-衰竭-丧失-终末期肾病、急性肾损伤网络与改善全球肾脏病预后定义时,脓毒症相关急性肾损伤合并发生率为0.52(95%CI 0.48-0.56)。
- 以接受肾脏替代治疗定义急性肾损伤时发生率最低(0.26,95%CI 0.24-0.28),以急性肾损伤网络评分定义时最高(0.57,95%CI 0.45-0.69;P<0.01)。
- 67项研究、29,455例参与者报告至少一项脓毒症相关急性肾损伤结局;末次随访时死亡比例为0.48(95%CI 0.43-0.53),存活者中仍接受透析比例为0.10(95%CI 0.04-0.17)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机临床试验和前瞻性队列研究;采用随机效应模型合并数据,异质性通过单协变量逻辑回归模型评估,偏倚风险采用改编的标准工具评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 脓毒症相关急性肾损伤的发生率和结局估计随所用急性肾损伤定义及是否纳入尿量标准而显著不同,解读流行病学数据时需注意定义差异。
- 脓毒症相关急性肾损伤在ICU脓毒症患者中常见,且死亡和持续肾功能损害风险高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To derive a pooled estimate of the incidence and outcomes of sepsis-associated acute kidney injury (SA-AKI) in ICU patients and to explore the impact of differing definitions of SA-AKI on these estimates.
DATA SOURCES: Medline, Medline Epub, EMBASE, and Cochrane CENTRAL between 1990 and 2023.
STUDY SELECTION: Randomized clinical trials and prospective cohort studies of adults admitted to the ICU with either sepsis and/or SA-AKI.
DATA EXTRACTION: Data were extracted in duplicate. Risk of bias was assessed using adapted standard tools. Data were pooled using a random-effects model. Heterogeneity was assessed by using a single covariate logistic regression model. The primary outcome was the proportion of participants in ICU with sepsis who developed AKI.
DATA SYNTHESIS: A total of 189 studies met inclusion criteria. One hundred fifty-four reported an incidence of SA-AKI, including 150,978 participants. The pooled proportion of patients who developed SA-AKI across all definitions was 0.40 (95% CI, 0.37-0.42) and 0.52 (95% CI, 0.48-0.56) when only the Risk Injury Failure Loss End-Stage, Acute Kidney Injury Network, and Improving Global Outcomes definitions were used to define SA-AKI. There was significant variation in the incidence of SA-AKI depending on the definition of AKI used and whether AKI defined by urine output criteria was included; the incidence was lowest when receipt of renal replacement therapy was used to define AKI (0.26; 95% CI, 0.24-0.28), and highest when the Acute Kidney Injury Network score was used (0.57; 95% CI, 0.45-0.69; p < 0.01). Sixty-seven studies including 29,455 participants reported at least one SA-AKI outcome. At final follow-up, the proportion of patients with SA-AKI who had died was 0.48 (95% CI, 0.43-0.53), and the proportion of surviving patients who remained on dialysis was 0.10 (95% CI, 0.04-0.17).
CONCLUSIONS: SA-AKI is common in ICU patients with sepsis and carries a high risk of death and persisting kidney impairment. The incidence and outcomes of SA-AKI vary significantly depending on the definition of AKI used.
参考来源
- Donaldson LH, Vlok R, Sakurai K, et al. Quantifying the Impact of Alternative Definitions of Sepsis-Associated Acute Kidney Injury on its Incidence and Outcomes: A Systematic Review and Meta-Analysis. Crit Care Med. 2024. PMID: 38557802. doi:10.1097/CCM.0000000000006284
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。